FBIO — Fortress Biotech, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1429260 ·
Last close
$1.82
Market Cap
$60.70M
52W High
$4.53
52W Low
$1.64
ADV30
234,844
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 19,159,000 | 13,275,000 | -7,193,000 | -5,845,000 | 280,215,000 | 152,186,000 | 103,194,000 |
| Jun 2026 | 18,718,000 | 12,575,000 | -10,006,000 | -468,000 | 316,715,000 | 196,576,000 | 110,629,000 |
| Mar 2026 | 16,038,000 | 9,820,000 | -7,739,000 | 110,373,000 | 356,874,000 | 255,841,000 | 154,500,000 |
| Dec 2025 | 16,079,000 | 10,639,000 | -4,789,000 | -3,937,000 | 185,548,000 | 79,381,000 | 123,365,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$125,920,000
Investing CF
$2,791,000
Financing CF
$-6,521,000
CapEx
—
Dividends Paid
$-473,000
Buybacks
$-14,335,000
EPS Diluted TTM
$3.30
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-624,147,000
Inventory
$8,156,000
Receivables
$36,752,000
ST Investments
—
EBIT TTM
$152,999,000
Pretax Income TTM
$145,856,000
Interest Exp TTM
$7,143,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$68,466,000
EBITDA
$-24,979,000
Free Cash Flow
$-17,136,250
Enterprise Value
$-38,611,132
Total Cash
$196,576,000
Total Debt
$53,316,000
Shares Out
33,350,993
Trailing EPS
$2.76
Book Value
$4.93
ROE
116.0%
ROA
-7.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 63,262,000 | -70,221,000 | 6,815,000 | 185,548,000 | 123,365,000 | 49,873,000 | -65,777,000 |
| Dec 2024 | 57,675,000 | -111,240,000 | -45,997,000 | 144,223,000 | 145,867,000 | 22,737,000 | -80,191,000 |
| Dec 2023 | 84,513,000 | -139,199,000 | -60,637,000 | 167,526,000 | 165,939,000 | 22,544,000 | -128,225,000 |
| Dec 2022 | 75,743,000 | -203,564,000 | -86,575,000 | 294,301,000 | 244,276,000 | 41,721,000 | -179,401,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$68,466,000
NetIncome TTM
$111,818,000
OpCashFlow TTM
—
Assets (Latest)
$316,715,000
Forward EPS
$-1.76
Max Pain — expiry 2027-01-15
max pain strike: $2.50 · spot: $1.89 · call oi: 2,880 · put oi: 502
Expected Move to 2027-01-15:
±$0.65
(34.39%) —
implied range
$1.24 –
$2.54
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KZIA | KAZIA THERAPEUTICS LTD | $60.68M | $5.31 | — |
| LFVN | Lifevantage Corp | $60.62M | $4.78 | — |
| ACRV | Acrivon Therapeutics, Inc. | $61.28M | $1.43 | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $62.03M | $3.01 | — |
| CTOR | CITIUS ONCOLOGY, INC. | $57.91M | $0.55 | — |
News headlines (Yahoo Finance, 1h cache)
Fortress Biotech, Inc. Q3 2026 Earnings Call Summary
2026-11-14 02:30 · Yahoo
Fortress Biotech: 3 Key Takeaways for Long-Term Investors
2026-11-13 14:38 · Yahoo
Fortress Biotech (FBIO) Q3 2026 Earnings Call Transcript
2026-11-13 13:58 · Yahoo
Fortress Biotech: Q3 Earnings Snapshot
2026-11-13 13:11 · Yahoo
Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
2026-11-13 13:00 · Yahoo
Fortress Biotech Q3 Earnings Call Highlights
2026-11-13 01:14 · Yahoo
Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
2026-11-10 21:05 · Yahoo
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript
2026-08-14 02:28 · Yahoo
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-13 20:05 · Yahoo
Fortress Biotech Q2 Earnings Call Highlights
2026-08-12 23:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.